IRIS
Simonelli, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.976
AS - Asia 3.339
EU - Europa 1.463
SA - Sud America 774
AF - Africa 180
Continente sconosciuto - Info sul continente non disponibili 175
OC - Oceania 3
Totale 12.910
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.799
SG - Singapore 2.028
BR - Brasile 616
CN - Cina 518
IT - Italia 478
VN - Vietnam 321
FI - Finlandia 230
IE - Irlanda 163
DE - Germania 131
NG - Nigeria 117
HK - Hong Kong 106
CA - Canada 105
FR - Francia 97
GB - Regno Unito 80
SE - Svezia 75
IN - India 61
AR - Argentina 56
NL - Olanda 53
TR - Turchia 45
BD - Bangladesh 42
ID - Indonesia 34
IQ - Iraq 30
EC - Ecuador 28
IL - Israele 27
PL - Polonia 27
MX - Messico 21
RU - Federazione Russa 19
CL - Cile 17
CO - Colombia 17
JP - Giappone 17
BE - Belgio 16
VE - Venezuela 16
ZA - Sudafrica 16
ES - Italia 15
PK - Pakistan 13
UA - Ucraina 13
CR - Costa Rica 12
SA - Arabia Saudita 12
PY - Paraguay 11
MA - Marocco 10
PH - Filippine 9
AT - Austria 8
JM - Giamaica 8
DZ - Algeria 7
EG - Egitto 7
MY - Malesia 7
TN - Tunisia 7
UY - Uruguay 7
UZ - Uzbekistan 7
HN - Honduras 6
KE - Kenya 6
LT - Lituania 6
PT - Portogallo 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
EE - Estonia 5
GT - Guatemala 5
KZ - Kazakistan 5
TW - Taiwan 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
EU - Europa 4
GE - Georgia 4
IR - Iran 4
LB - Libano 4
NI - Nicaragua 4
PE - Perù 4
AL - Albania 3
AU - Australia 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
KR - Corea 3
LV - Lettonia 3
NP - Nepal 3
PS - Palestinian Territory 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CG - Congo 2
ET - Etiopia 2
GA - Gabon 2
GR - Grecia 2
HR - Croazia 2
JO - Giordania 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
MK - Macedonia 2
OM - Oman 2
PA - Panama 2
AF - Afghanistan, Repubblica islamica di 1
AG - Antigua e Barbuda 1
Totale 12.721
Salva come PNG Salva come JPEG
Città #
Singapore 898
Wilmington 707
Chandler 508
Ashburn 479
San Jose 397
Dallas 391
The Dalles 315
San Mateo 300
Helsinki 229
New York 227
Milan 216
Shanghai 216
Ann Arbor 189
Council Bluffs 167
Dublin 163
Princeton 146
Beijing 127
Lawrence 127
Leawood 119
Benin City 117
Ho Chi Minh City 109
Hong Kong 102
Phoenix 100
Santa Clara 94
Los Angeles 93
Woodbridge 81
Boardman 80
Paris 72
Hanoi 67
São Paulo 63
Rome 62
Fairfield 60
Toronto 48
Amsterdam 44
London 39
Buffalo 38
Seattle 37
Chicago 29
Kocaeli 29
Naples 27
San Diego 26
Orem 23
Warsaw 22
North Bergen 21
Figino 20
Atlanta 18
Miami 18
Montreal 18
Rio de Janeiro 18
Brooklyn 17
Da Nang 16
Belo Horizonte 15
Brussels 15
Haiphong 15
Pune 15
Boston 14
Chennai 13
Charlotte 12
Denver 12
Norwalk 12
Baghdad 11
Brasília 11
Cleveland 11
Columbus 11
Guayaquil 11
Mexico City 11
Porto Alegre 11
Queens 11
Tokyo 11
Erbil 10
Hillsboro 10
Las Vegas 10
Louisville 10
Manchester 10
Philadelphia 10
San Francisco 10
The Bronx 10
Curitiba 9
Milwaukee 9
San José 9
Santiago 9
Stockholm 9
Abbiategrasso 8
Dhaka 8
Jacksonville 8
Monmouth Junction 8
Munich 8
Washington 8
Detroit 7
Falkenstein 7
Fortaleza 7
Johannesburg 7
Reston 7
San Antonio 7
Tashkent 7
Thái Nguyên 7
Arlington 6
Baltimore 6
Biên Hòa 6
Buenos Aires 6
Totale 8.004
Salva come PNG Salva come JPEG
Nome #
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 161
MODULATION OF IL-2 CANCER IMMUNOTHERAPY BY CYCLOOXYGENASE (COX)-2 INHIBITORS: THERAPEUTIC AND BIOLOGICAL RESULTS OF IL-2 PLUS CELECOXIB IN METASTATIC RENAL CELL CANCER (RCC) PROGRESSING ON IL-2 ALONE 149
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy 147
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 143
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 139
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 137
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 135
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 132
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 131
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 130
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 127
Treatment of malignant pleural mesothelioma: current status and future directions 126
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 124
COVID-19 and liver cancer clinical trials: not everything is lost 120
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 120
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 115
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 115
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 114
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 114
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 113
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 112
Advances in the biology of malignant pleural mesothelioma 112
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 108
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 107
Reproducibility of the WHO classification of thymomas: practical implications 107
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 104
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 104
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 103
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 103
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 102
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 100
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 100
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 99
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 98
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 97
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 96
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 96
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 95
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 95
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 95
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 94
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 94
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 93
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 93
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 93
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 93
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 92
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 92
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 92
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 91
Neutrophils in Gliomas 91
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 91
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 91
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 90
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 90
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 89
Imaging biomarkers in primary brain tumours 89
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 89
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 89
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 89
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 88
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 88
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 88
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 87
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 86
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 85
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events 84
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors 84
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 84
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report 84
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 83
Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study 83
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome 81
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 81
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 80
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 79
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 78
Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series 78
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes 78
Brain metastases and next-generation anticancer therapies: a survival guide for clinicians 78
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 77
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 77
Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions 76
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 76
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study 76
Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study 75
Intensified chemotherapy with stem-cell rescue in germ-cell tumors 75
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 75
First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer 75
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey 74
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 74
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study 74
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 73
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 73
Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future 72
Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification 71
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 71
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 71
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 70
Future developments in the management of malignant pleural mesothelioma 70
Totale 9.582
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.691
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.691
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022639 0 0 0 139 4 6 28 102 55 71 199 35
2022/20231.536 285 66 162 148 120 99 3 119 261 153 107 13
2023/20241.113 58 108 171 39 45 251 88 47 11 32 109 154
2024/20251.553 33 17 10 27 33 162 64 166 270 359 197 215
2025/20264.619 609 416 370 484 134 264 1.095 241 236 299 175 296
2026/20271.930 617 347 680 286 0 0 0 0 0 0 0 0
Totale 12.910